5 Insightful Analyst Questions From Tandem Diabetes's Q3 Earnings Call

Tandem Diabetes’ third quarter was marked by improved operational efficiency and commercial execution, resulting in a positive market reaction. Management credited the quarter’s performance to the ongoing modernization of U.S. commercial operations, increased pricing contributions from both traditional and pharmacy channels, and early traction from new product offerings. CEO John Sheridan highlighted that changes in sales processes and organizational restructuring began to yield tangible results, particularly through better sales productivity and a strong mix of customers adopting both t:slim and Mobi pump platforms. The company’s focus on expanding pharmacy benefit access and a growing portfolio approach helped offset volume headwinds and supported margin improvements.

Is now the time to buy TNDM? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Tandem Diabetes’s Q3 Earnings Call

• Matthew Miksic (Barclays) asked about growth catalysts and cadence for 2026. CEO John Sheridan highlighted that pipeline launches—especially Mobi Tubeless and expanded pharmacy access—would build momentum progressively through next year.
• Larry Biegelsen (Wells Fargo) inquired about the sustainability and size of pricing benefits from pharmacy channel expansion. CFO Leigh Vosseller indicated current trends provide a baseline, and more details will be shared after year-end data is analyzed.
• Christopher Pasquale (Nephron Research) questioned assumptions underlying fourth quarter seasonality. Vosseller explained that shipment seasonality is shaped by historical renewal patterns and renewed opportunities, with about 30% of annual shipments expected in the fourth quarter.
• Richard Newitter (Truist Securities) asked about the risk of competitive pricing pressure as more companies enter the pharmacy channel. Vosseller acknowledged long-term pricing risk but said the near-term opportunity justifies the current strategy.
• Joanne Wuensch (Citibank) sought clarity on the positioning of Sigi as a next-generation Mobi product. Sheridan confirmed that Sigi development is now integrated into the Mobi family, with Mobi Tubeless prioritized for launch.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be watching (1) the pace of pharmacy channel adoption and its impact on gross margins, (2) the commercial rollout and patient uptake of new products like Mobi Tubeless and expanded CGM integrations, and (3) the successful transition to direct sales in key European markets. Execution of the multichannel market access strategy and incremental operating leverage will also be critical for sustained improvement.

Tandem Diabetes currently trades at $18.08, up from $13.32 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free for active Edge members).

The Best Stocks for High-Quality Investors

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.